Hanmi Pharm announced on March 30 that it entered into partnership for the joint development and commercialization of immunologic anti-cancer double antibodies with Innovent Biologics Co. of China.
An immunologic anti-cancer double antibody co-developed by both companies is able to perform both anti-cancer immunotherapy for activating immune cells and a cancer therapy to attack cancer cells only. The antibody is expected to enter the first phase clinical trial in 2019.
Pentambody, a platform technology developed by Beijing Hanmi Pharma, a Chinese subsidiary of Hanmi Pharma, was applied as a candidate material for this drug. Pentambody is based on next-generation dual antibody platform technology in which one antibody combines with two different targets simultaneously. Hanmi Pharm is developing a variety of dual antibody drugs with various targets using Pentambody technology.
Under the agreement, Hanmi will lead the development, licensing and commercialization of the drug worldwide excluding China. Innovent will be responsible for the development, licensing, commercialization and production of the product in China.
"Innovent is a competent company that is already developing products with global companies in the sector of immunologic anti-cancer drugs,” said Kwon Se-chang, CEO of Hanmi Pharm. “This partnership will empower our company to take another big step towards developing innovative immunologic anti-cancer bispecific antibodies,” he added.